IRVINE, Calif., June 1 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low Perfusion pulse oximetry, and Fukuda Denshi, a leading global manufacturer of electronic medical devices and patient monitors, today jointly announced a worldwide technology licensing agreement to integrate Masimo Rainbow SET Pulse CO-Oximetry technology into Fukuda Denshi's next generation patient monitors. The agreement allows Fukuda Denshi to incorporate the breakthrough noninvasive blood constituent measurement capabilities of Masimo Rainbow SET to detect and treat life-threatening conditions earlier.
The breakthrough noninvasive blood constituent monitoring capabilities of Masimo Rainbow SET Pulse CO-Oximetry allow for continuous monitoring of hemoglobin, carbon monoxide, methemoglobin, PVI for fluid responsiveness, perfusion index, and measure-through motion pulse oximetry. With Masimo Rainbow SET, the ability to detect internal bleeding, carbon monoxide poisoning, methemoglobinemia, fluid responsiveness, perfusion, saturation, and pulse rate quickly, easily and continuously can help save lives and improve patient outcomes.
According to Kotaro Fukuda, President and CEO, "Our overriding goal is to provide innovative medical devices with superior performance and value. The integration of Masimo Rainbow SET Pulse CO-Oximetry measurements will allow us to design and manufacture state-of-the-art patient monitors that advance the delivery of healthcare. Our combined product offering will allow clinicians to more thoroughly assess a patient's physiological status and make better clinical and treatment decisions."
OEM President, Rick Fishel, stated, "Fukuda Denshi is the first patient monitoring manufacturer in Japan to integrate Masimo Rainbow SET Pulse CO-Oximetry technology. This first-to-market commitment and strategy provides Fukuda Denshi customers with access to an upgradeable platform of blood constituent monitoring parameters, leveraging additional clinical intelligence and vital noninvasive blood constituent data on their multiparameter patient monitor."
About Fukuda Denshi
Fukuda Denshi Co. Ltd., is a leading manufacturer of electronic medical devices including a unique set of world-class patient monitoring products. Founded in 1939, Fukuda Denshi is one of Japan's largest medical manufacturers with global offices throughout the world and a network of distributors serving Asia, Europe, North & South America, and Africa. Additional information about Fukuda Denshi and its products may be found at www.fukuda.co.jp
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET® Pulse CO-Oximetry™, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI®, in addition to SpO2, pulse rate, and perfusion index (PI). In 2009, Masimo introduced Masimo Rainbow SET® Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's Rainbow platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions that Fukuda Denshi's 2010 or future generation patient monitors will feature Masimo Rainbow SET technology; that all Masimo Rainbow SET capabilities will be available in Fukuda Denshi patient monitors; that integration of Masimo Rainbow SET technology and capabilities will allow clinicians using Fukuda Denshi patient monitors to detect internal bleeding, carbon monoxide poisoning, methemoglobinemia, fluid responsiveness, perfusion, saturation, and pulse rate quickly, easily and continuously in all patients; and that using Masimo Rainbow SET will help save lives and improve patient outcomes, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.